Combination antiretroviral therapy with protease inhibitors in HIV-infected pregnancy

Journal of Perinatal Medicine

Volumn 40, Issue 1, 2012, Pages 51-55

  Dola, Chi P ^a   Khan, Rubina ^b   DeNicola, Nathaniel ^a   Amirgholami, Mahin ^a   Benjamin, Tara ^a   Bhuiyan, Azad ^c   Longo, Sherri ^b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OCHSNER MEDICAL CENTER   (United States)

^c JACKSON STATE UNIVERSITY   (United States)

Author keywords

Low birth weight; Preterm birth; Protease inhibitors

Indexed keywords

AMPRENAVIR; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; GESTATIONAL AGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PREGNANCY; PREGNANCY OUTCOME; PREMATURITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIRTH WEIGHT; FEMALE; HIV INFECTIONS; HUMANS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREMATURE BIRTH; PROTEASE INHIBITORS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84856946254     PISSN: 03005577     EISSN: 16193997     Source Type: Journal    
DOI: 10.1515/JPM.2011.111     Document Type: Article

References (13)

1. Centers for Disease Control and Prevention. Report of the NIH Panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR Morb Mortal Wkly Rep. 1998;47:1-80.
2. Conor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331:1173.
3. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1 infected women and prevention of perinatal transmission. J Acquir Immune Defic Syndr. 2002;29:484-94. (Pubitemid 34456340)
4. European collaborative study and the Swiss Mother+Child HIV Cohort Study (2000). Combination antiretroviral therapy and duration of pregnancy. AIDS. 2000;14:2913-20.
5. Grosch-Woerner I, Puch K, Maier RF, Niehues T, Notheis G, Patel D, et al. Multicenter Interdisciplinary Study Group Germany/Austria. Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women. HIV Med. 2008;9,6-13.
6. Iams JD, Berghella, V. Care for women with prior preterm birth. Am J Obstet Gynecol. 2010;203:89-100.
7. Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Use of antiretro-viral therapy in pregnant HIV infected women and the risk of premature delivery: a meta-analysis. AIDS. 2007;21:607-15.
8. Lorenzi P, Spicher VM, Laubereau B, Hirschel B, Kind C, Rudin C, et al. Antiretroviral therapies in pregnancy: maternal, fetal, and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS 1998;12:F241-47.
9. Morris AB, Cu-Uvin S, Harwell JI, Garb J, Zorrilla C, Vajaranant M, et al. Multicenter review of protease inhibitors in 89 pregnancies. J Acquir Immune Defic Syndr. 2000;25:306-11. (Pubitemid 32107161)
10. Morris AB, Dobels AR, Cu-Uvin S, Zorrilla C, Anderson J, Harwell JI, et al. Protease inhibitor use in 233 pregnancies. J Acquir Immune Defic Syndr. 2005;40:30-5.
11. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1-a meta-analysis of 15 prospective cohort studies. The International Perinatal HIV Group. N Engl J Med. 1999;340:977-87.
12. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS. 2007;21:1019-26. (Pubitemid 46684333)
13. Tuomala RE, Shapiro DE, Mofensen LM, Bryson Y, Culnane M, Hughes MD, et al. Antiretroviral therapy during pregnancy and risk of an adverse outcome. N Engl J Med. 2002;346:1863-70. (Pubitemid 34603030)